Igor S. Yavelov

Igor S. Yavelov

Auto-generated profile, based on publicly available information

Igor S. Yavelov

National Medical Research Center for Therapy and Preventive Medicine

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in International Journal of Cardiology
Verified
Journal Article
Open access
MNMarkku S. Nieminen
Markku S. Nieminen
KDKenneth Dickstein
Kenneth Dickstein
CFCândida Fonseca
Cândida Fonseca
JSJose Magaña Serrano
Jose Magaña Serrano
JPJohn Parissis
John Parissis
RZRobert Zymliński
Robert Zymliński
End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.

6 April 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ESE. V. Shlyakho
E. V. Shlyakho
AKA. O. Konradi
A. O. Konradi
GAG. P. Arutyunov
G. P. Arutyunov
AAA. G. Arutyunov
A. G. Arutyunov
ABAndrei Evgen'evich Bautin
Andrei Evgen'evich Bautin
AYA. N. Yakovlev
A. N. Yakovlev
Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic

1 April 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
AKA. V. Kontsevaya
A. V. Kontsevaya
AKA. M. Kalinina
A. M. Kalinina
SASergey Avdeev
Sergey Avdeev
MAM. V. Agaltsov
M. V. Agaltsov
БДБ. Ю. Джонова
Б. Ю. Джонова
Создание руководства поддержано Советом по терапевтическим наукам отделения клинической медицины Российской академии наук.

30 March 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
EPElizaveta Panchenko
Elizaveta Panchenko
TBTatyana Balakhonova
Tatyana Balakhonova
NDN. M. Danilov
N. M. Danilov
AKA. L. Komarov
A. L. Komarov
EKE. S. Kropachyova
E. S. Kropachyova
IYI. S. Yavelov
I. S. Yavelov
Disclaimer.The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

8 July 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OAO. V. Averkov
O. V. Averkov
OBOlga Barbarash
Olga Barbarash
SBSergey Boytsov
Sergey Boytsov
EVElena Vasilieva
Elena Vasilieva
ODOxana M. Drapkina
Oxana M. Drapkina
МГМ. Ю. Гиляров
М. Ю. Гиляров
Дифференцированный подход в диагностике, формулировке диагноза, ведении больных и статистическом учете инфаркта миокарда 2 типа (согласованная позиция)

25 November 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
AKA. L. Komarov
A. L. Komarov
EPElizaveta Panchenko
Elizaveta Panchenko
ISI. I. Staroverov
I. I. Staroverov
RSR. M. Shahnovich
R. M. Shahnovich
IYI. S. Yavelov
I. S. Yavelov
The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.